key: cord-0901525-djrxsk1c authors: Schwartz, Kayleigh M.; Honstain, Chelsea; Spruit, Jessica L.; Harris, Megan title: Allogeneic Hematopoietic Stem Cell Transplant for Acute Lymphoblastic Leukemia in a Pediatric Patient following COVID-19 infection Complicated by MIS-C date: 2022-01-31 journal: J Pediatr Health Care DOI: 10.1016/j.pedhc.2022.01.006 sha: 4a2f9aabeef47af2279ccb3b55b984b2eda1f897 doc_id: 901525 cord_uid: djrxsk1c The COVID-19 pandemic has impacted the care of countless individuals, including pediatric oncology patients. The initial lack of knowledge about the disease course and implications of infection led to delays in treatment to minimize additional harm. In pediatric oncology, unnecessary delays in chemotherapy or hematopoietic stem cell transplantation (HSCT) may increase the risk of disease relapse. This case report describes one high-risk pediatric oncology patient's clinical course through HSCT immediately following COVID-19 infection complicated by multisystem inflammatory syndrome in children (MIS-C). The disease course, monitoring, long term outcome and recommendations for future research is reviewed. patient's clinical course through HSCT immediately following COVID-19 infection complicated by multisystem inflammatory syndrome in children (MIS-C) . The disease course, monitoring, long term outcome and recommendations for future research is reviewed. The SARS-CoV2 (COVID-19) pandemic has greatly impacted the care of pediatric oncology patients worldwide. Although pediatric patients generally have a milder disease course, concerns remain regarding the increased risk of severe complications in immunocompromised populations. There is a paucity of data available on children with cancer presenting with COVID-19 infection and optimal management of their oncological disease and concurrent viral infection. While pediatric oncology patients have had similar comorbidities to adult oncology patients, they have experienced less symptomology and lower mortality rates compared to their adult counterparts (Belsky et al., 2021) . Avoidance of intensive chemotherapy or a moderate reduction of chemotherapy during the acute phase of illness with SARS-CoV2 infection is recommended (Dannan et al., 2020; Sahu et al., 2020) ; however, this must be balanced with their cancer treatment as delays may lead to progression of their underlying malignancy and increase mortality risk. This case report examines the allogeneic hematopoietic stem cell transplant (HSCT) course of a pediatric patient with B-cell acute lymphoblastic leukemia (B-ALL) who was diagnosed and treated for COVID-19 and MIS-C 12 weeks prior to an unrelated donor HSCT. A three-year-old male was diagnosed in April 2019 with B-ALL CD19+, CD45+, with KMT2A/MLLT1 rearrangement, (t(11: (19) (q23:p13)) and received chemotherapy according to a standard risk Children's Oncology Group (COG) protocol. He achieved an initial remission, only to have an isolated marrow relapse in October 2020 during maintenance therapy. On day 19 of re-induction therapy (day one of illness) the patient developed febrile neutropenia. His initial blood cultures returned positive for Rothia mucilaginosa and cefepime and vancomycin were prescribed. Further chemotherapy was deferred due to febrile neutropenia, bacteremia and concern for sepsis. On day three of illness the patient remained persistently febrile and tachycardic despite broad spectrum antimicrobials. He required fluid resuscitation and increased transfusion support to maintain hemodynamic stability. In addition, high flow nasal cannula was prescribed. When his respiratory symptoms did not improve following diuresis, a naso-pharyngeal COVID-19 polymerase chain reaction (PCR) was obtained and resulted positive. Following consultation with the Pediatric Infectious Disease team, Multisystem Inflammatory Syndrome in Children (MIS-C) serologic studies were obtained including complete blood counts (CBC), procalcitonin, CRP, serum ferritin, complete metabolic panel, D-dimer and brain natriuretic peptide (BNP) ( Table 1) . Although his serum D-dimers were elevated and concerning for a hypercoagulable state, deep vein thrombosis (DVT) prophylaxis was held due to concurrent thrombocytopenia. A five-day course of remdesivir was prescribed. Convalescent plasma was considered, however his COVID IgG testing resulted positive, rendering him ineligible. Given the risk of cardiac complications in hyperinflammatory states, an echocardiogram (ECHO) was obtained on day five of illness and revealed low-normal function and dilated right coronary artery without aneurysm in addition to a small pericardial effusion. The patient continued to be febrile with significantly elevated inflammatory markers. A panel of cytokines and inflammatory proteins were measured at this time with serum levels of interleukin (IL)-2R, IL-6, IL-8 and IL-13 markedly elevated (Table 2 ). In addition, serum CRP, ferritin, BNP, and Ddimer levels were continuing to increase (Table 1 ). At this time the patient met the Center for Disease Control and Prevention (CDC) criteria for MIS-C and anakinra, an IL-1 receptor antagonist, and two doses of intravenous immunoglobulin (IVIG) were administered. Systemic corticosteroids were not initially utilized due to prolonged neutropenia and concurrent bacteremia; however, on day seven of illness, dexamethasone was prescribed for a 10-day course. The patient's clinical status and serological studies (CBC, CRP, procalcitonin, ESR, Ddimer, BNP) showed initial improvements with these measures. Based upon the microbiologic sensitivity assays for the Rothia mucilaginosa, his antimicrobial coverage was modified, with the patient completing a seven-day treatment course of clindamycin with empiric antibiotics continuing due to his ongoing neutropenia. On day 10 of illness, the patient was in septic shock as with persistent fever, fluid refractory hypotension, and a precipitous hemoglobin drop. He required multiple fluid boluses, as well as platelet and red cell transfusions. Given his prolonged neutropenia, his empiric antibiotics were again broadened per institutional standards. Repeat blood and urine cultures demonstrated no additional infections and antibiotics were then de-escalated with improved clinical status on day 14 of illness. Once stabilized, the patient resumed vincristine for leukemic disease control. Though inflammatory markers initially improved with anakinra and a 10-day systemic steroid course, the patient continued to experience recurrent daily fevers and ongoing tachycardia. Repeat COVID-19 testing on days 16 and 17 of illness were negative. A repeat ECHO showed a decreased ejection fraction from the previous study with low normal systolic function of the left ventricle, left ventricular global strain decreased, and pericardial effusion. An interleukin panel was repeated on day 22 of illness and showed normal to improved values of IL 2R, IL-6, IL-8 and IL-13 (Table 2) . Therefore, anakinra was discontinued; however, due to the patient's clinical picture and worsening fever curve, methylprednisolone was resumed on day 23 of illness. An infectious work-up was completed including viral and fungal studies and a computed tomography (CT) of the sinuses, chest, abdomen, and pelvis with no obvious infection source. Given concern for thrombosis in the setting of MIS-C, aspirin was also initiated on day 25 of illness. The patient's clinical status and serological studies, specifically his serum CRP, ferritin, BNP and D-Dimer, began to improve after initiation of methylprednisolone. Following resolution of symptoms, he was transitioned to oral steroids on day 26 of illness with a slow corticosteroid taper planned. He was tapered off systemic corticosteroids after seven weeks of treatment. A repeat marrow aspirate and biopsy revealed a remission status and minimal residual disease (MRD) negative, and he proceeded with consolidation chemotherapy per protocol on day 34 of illness. After completion of consolidation therapy, he was consented for HSCT due to his history of early leukemic relapse. A pre-transplant workup ECHO revealed improved cardiac function with resolved pericardial effusion. Baseline CT scans were repeated post COVID/MIS-C and prior to HSCT and were negative for infectious processes. The patient was admitted for a matched unrelated allogeneic HSCT 12 weeks post COVID-19/MIS-C treatment. At the time of admission his serological inflammatory markers had normalized (Table 1) . He completed a myeloablative preparative regimen of cyclophosphamide and total body irradiation (1200 cGy) followed by a 10/10 HLA matched unrelated allogeneic stem cell transplant with a cell dose of 3.8 x 10^6 CD34+ cell/kg and 6 x 10^8 TNC/kg. He chimerism 98% donor, and CD33 chimerism 100% donor. An ECHO was also completed at this time due to his history of COVID/MIS-C which revealed normal bilateral ventricular function without hypertrophy and stable left ventricular ejection fraction (LVEF) at 58%. For the general population who test positive for COVID-19, few individuals can transmit the virus after 10 days from symptom onset (CDC, 2021) . In severely immunocompromised patients, viral shedding has been noted to last much longer with PCR results remaining positive for weeks to months post initial infection (Sahu et al., 2020) . This prompts concern regarding decisions to proceed with oncology treatment plans and potential for recurrence of COVID-19 symptoms. Immunocompromised children have had favorable outcomes despite COVID-19 infections and when receiving necessary treatment for their malignancies without severe adverse effects (Dannan et al., 2020) . Hematopoietic stem cell transplant (HSCT), is an example of treatment that needs to be carefully considered for oncology patients with COVID-19 infection. Seven adult patients with acute leukemia who received allogeneic HSCT post COVID-19 infections did not experience a more complicated post-transplant course (Christopeit et al., 2021) . Additionally, no reactivation of COVID-19 was observed in this case series (Christopeit et al., 2021) . Current recommendations from the American Society for Transplantation and Cellular Therapy (ASTCT) for patients undergoing HSCT or cellular therapy who are acutely infected with COVID-19, are to defer transplant or cell infusion for a minimum of 14-21 days with at least two consecutive negative PCR tests spaced 24 hours apart with absence of symptoms (Waghmare et al., 2020) . For patients with high risk underlying disease, careful consideration on a case-by-case basis regarding the decision to proceed with transplant is recommended (Waghmare et al., 2020) . Additional considerations in progression of oncologic management also includes the hyperinflammatory response associated with COVID-19. As the pandemic progressed, it became evident that children presented with different symptoms than adults. Numerous pediatric cases presented with hyperinflammatory shock and multi-organ system involvement similar to Kawasaki Disease (Ahmed et al., 2020) . These children exhibited high levels of inflammatory markers (IL-6, ferritin, ESR, CRP), persistent fever, rash, gastrointestinal, cardiovascular and respiratory symptoms (Feldstein et al., 2020) . In a majority of these cases, children were shown to be positive for SARS-CoV2 either via RT-PCR or serological testing or were known to have recent direct exposure to an infected individual (Feldstein et al., 2020) . As more cases evolved globally, the CDC, the World Health Organization (WHO) and the Royal College of Paediatrics and Child Health labelled this illness MIS-C (Table 3 .0); (CDC, 2021; WHO, 2021) . The current hypotheses of the emergence of MIS-C are attributed to a delayed immunologic response to COVID-19 infection, molecular mimicry, and viral superantigens that activate an immunological host response to virus-infected cells mediated by antibodies, T-cells, or macrophages (Belay et al., 2021; Pandrowala et al., 2021) . A cross-sectional study identified 1816 pediatric patients in the United States as having met the diagnostic criteria for MIS-C (Belay et al., 2021) . Children who were hospitalized with COVID-19 also exhibited clinical manifestations that overlapped with that of MIS-C (Belay et al., 2021) . While available literature and data is expanding on general pediatric patients who have experienced this syndrome, there is limited data on describing the clinical course of pediatric oncology patients who have MIS-C. Two case studies have described pediatric patients with leukemia who presented with SARS-CoV2 related MIS-C; in one case the patient was treated with methylprednisolone and in the other case no specific MIS-C treatment was prescribed. Both patients recovered and proceeded with their oncologic treatment plan (Al-Haddad et al., 2020; Pandrowala et al., 2021) . (Henderson et al., 2020) . We recognize the limitations of our single case study patient. The experience of one patient at our institution may not be representative of broader transplant outcomes. However, our case summarizes a unique illness trajectory and adds to the paucity of literature related to the safety and feasibility of HSCT following COVID-19 infection complicated by MIS-C. There are several reports of children with hematologic and oncologic diagnoses becoming infected with COVID-19 (Gampel et al., 2020) . Additionally, there are case reports and summaries of patient experiences when infected with COVID-19 following HSCT (Vicent et al., 2020) . There is very limited published experience, for HSCT patients following COVID-19 infection and no case reports of HSCT following COVID-19 infection complicated by MIS-C (Christopeit et al., 2021; Cuzzubbo et al., 2021; Stanley et al., 2021) . The authors declare no conflicts of interest and no additional source of support All criteria must be met: Multisystem inflammatory syndrome in children: A systematic review Newly diagnosed acute lymphoblastic leukemia in a child with COVID-19 complicated by MIS-C: A case report from Kuwait Trends in geographic and temporal distribution of US children with Multisystem Inflammatory Syndrome during the COVID-19 pandemic COVID-19 in immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid organ transplant patients Multisystem Inflammatory Syndrome in Children (MIS-C) associated with coronavirus disease 2019 Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection Planned hematopoietic stem cell transplantation in a 17-month-old patient with high-risk acute myeloid leukemia and persistent SARS-CoV-2 infection Clinical course of COVID-19 among immunocompromised children: a clinical case series Multisystem Inflammatory Syndrome in U.S. children and adolescents COVID-19 disease in New York City pediatric hematology and oncology patients American College of Rheumatology Clinical Guidance for pediatric patients with Multisystem Inflammatory Syndrome in Children (MIS-C) associated with SARS-CoV-2 and hyperinflammation in COVID-19. Version 2 SARS-COV-2 related multisystem inflammatory syndrome in an immunocompromised child with leukemia. Pediatric Blood and Cancer COVID-19 pandemic and impact on hematopoietic stem cell transplantation Haploidentical hematopoietic stem cell transplantation is even more advantageous during the COVID-19 pandemic COVID-19 in pediatric hematopoietic stem cell transplantation: The experience of Spanish Group of Transplant (GETMON/GETH) Guidelines for COVID-19 management in hematopoietic stem cell transplantation and cellular therapy recipients Multisystem inflammatory syndrome in children and adolescents with COVID-19 Rash, bilateral non purulent conjunctivitis or mucocutaneous inflammation signs (oral, hands or feet) Hypotension or shock 3. Cardiac dysfunction, pericarditis, valvulitis or coronary abnormalities Acute gastrointestinal symptoms SARS-CoV2 infection (RT-PCR, serology or antigen test All criteria must be met Age < 21 years with fever, laboratory evidence of inflammation and evidence of clinically severe illness requiring hospitalization with multisystem (> 2) organ involvement Positive for current or recent SARS-CoV2 infection by RT-PCR, serology or antigen test; outlines the CDC's and WHO's case definitions of MIS-C. Patients who meet these criteria and who also fulfill full or partial criteria for Kawasaki disease should be considered to have MIS-C and should be reported Multisystem inflammatory syndrome in children and adolescents temporally related to COVID-19 MIS-C: Multisystem inflammatory syndrome in children; RT-PCR: real-time polymerase chain reaction Laboratory evidence of inflammation: CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; LDH: lactate dehydrogenase; IL-6: interleukin-6; BNP: brain natriuretic peptide, fibrinogen, procalcitonin, d-dimer, elevated neutrophils, reduced lymphocytes, low albumin (CDC 2021) Laboratory evidence of coagulopathy: PT: prothrombin time Consent was provided by the patient's parents to publish information regarding his medical condition and treatment.